Adaptive Biotechnologies Corporation - notizie pubblicate 188 - letture 6.278
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology
Pdf version the t-cell therapy product candidate contains a neoantigen-specific t-cell receptor (tcr) identified and characterized through adaptive's tcr discovery platform seattle ...
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Adaptive Biotechnologies Reports First Quarter 2023 Financial Results
Pdf version seattle, may 03, 2023 (globe newswire) -- adaptive biotechnologies corporation ("adaptive biotechnologies") (nasdaq: adpt), a commercial stage biotechnology c ...
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Adaptive Biotechnologies Reports First Quarter 2023 Financial Results - Form 8-K
Adaptive biotechnologies reports first quarter 2023 financial results seattle, may 03, 2023 (globe newswire) - adaptive biotechnologies corporation ("adaptive biotechnologies& ...
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Quarterly Report for Quarter Ending March 31, 2023 (Form 10-Q)
United states securities and exchange commission washington, dc 20549 form 10-q (mark one) ☒ quarterly report pursuant to section 13 or 15(d) of the securities exchange act of 19 ...
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Adaptive Biotechnologies Q1 2023 Earnings Presentation
First quarter 2023 earnings conference call safe harbor this presentation has been prepared by adaptive biotechnologies corporation ("we," "us," "our," ...
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Annual Report - Form ARS
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer adaptive biotechnolo ...
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Proxy Statement - Form DEF 14A
Table of contents united states securities and exchange commission washington, d.c. 20549 schedule 14a proxy statement pursuant to section 14(a) of the securities exchange act of 1 ...
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Additional Proxy Soliciting Materials - Form DEFA14A
United states securities and exchange commission washington, d.c. 20549 schedule 14a (rule 14a-101) schedule 14a information proxy statement pursuant to section 14(a) of the securi ...
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Adaptive Biotechnologies to Participate in the BofA Securities 2023 Healthcare Conference
Pdf version seattle, april 25, 2023 (globe newswire) -- adaptive biotechnologies corporation ("adaptive biotechnologies") (nasdaq: adpt), a commercial stage biotechnology ...
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Statement of Changes in Beneficial Ownership - Form 4
Form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchange commission washingt ...
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline
Pdf version collaboration will cover existing and future programs to aid in the development and commercialization of investigational medicines for hematologic malignancies seattle, ...
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Management Change - Form 8-K
8-k united states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of r ...
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Adaptive Biotechnologies to Report First Quarter Financial Results on May 3, 2023
Pdf version seattle, april 06, 2023 (globe newswire) -- adaptive biotechnologies corporation ("adaptive biotechnologies") (nasdaq: adpt), a commercial stage biotechnology ...
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Statement of Changes in Beneficial Ownership - Form 4
Form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchange commission washingt ...
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Statement of Changes in Beneficial Ownership - Form 4
Form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchange commission washingt ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti